Alimera Sciences
6120 Windward Parkway
Suite 290
Alpharetta
Georgia
30005
United States
Tel: 678-990-5740
Fax: 678-990-5744
Website: http://www.alimerasciences.com/
340 articles about Alimera Sciences
-
Alimera Sciences Announces Second Quarter 2022 Financial Results
7/27/2022
Alimera Sciences, Inc. today announced financial results for the second quarter of 2022.
-
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
7/26/2022
Alimera Sciences, Inc. announced that the PALADIN Phase 4 Study confirms the safety of ILUVIEN® 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients with diabetic macular edema.
-
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
7/22/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), announces today that it will report second quarter financial results on Wednesday, July 27, 2022, before the market opens.
-
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France Partner Horus Pharma to launch ILUVIEN
7/22/2022
Alimera Sciences, Inc. will launch ILUVIEN ® for non-infectious posterior uveitis in France, through its distribution partner, Horus Pharma S.A.S. (Horus).
-
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual CongressILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference.
7/13/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN ® data will be overviewed in various scientific abstracts at the American Society of Retina Specialists (ASRS) conference being held in New York, New York from July 13-16.
-
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
7/8/2022
Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval.
-
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
6/8/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announced today that its partner, Ocumension Therapeutics (“Ocumension”) received approval from the National Medical Products Administration for its IND application to begin the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.
-
Alimera Sciences to Present at the LD Micro Invitational XII Conference
6/2/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XII Conference. The conference is being held on June 7 – 9, 2022.
-
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
5/12/2022
Alimera Sciences, Inc. announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN® U.S. label to mitigate the risk of uncontrolled intraocular pressure elevation.
-
Alimera Sciences Reports First Quarter 2022 Results
5/9/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2022.
-
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
5/6/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on Monday, May 9, 2022, prior to the market open.
-
Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress
4/28/2022
Alimera Sciences, Inc. announced that ILUVIEN® will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
-
Alimera Sciences to Present at the Q1 Investor Summit Conference
3/2/2022
Alimera Sciences, Inc. announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
2/24/2022
Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2021.
-
Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
2/23/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announced today that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology.
-
Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update
2/17/2022
Alimera Sciences, Inc. announces today that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, prior to the market open.
-
Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in SpainILUVIEN received pricing approval for non-infectious posterior uveitis indication in December
2/7/2022
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch ILUVIEN® for non-infectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill).
-
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
2/4/2022
Alimera Sciences, Inc. today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.
-
Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences
1/5/2022
Alimera Sciences, Inc. announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in two investor conference events in January.